Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Authors
Keywords
Hepatocellular carcinoma, Metronomic capecitabine, Second-line chemotherapy, Survival, Toxicity
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 144, Issue 2, Pages 403-414
Publisher
Springer Nature
Online
2017-12-16
DOI
10.1007/s00432-017-2556-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
- (2017) Andrea Casadei Gardini et al. Scientific Reports
- Capecitabine in advanced hepatocellular carcinoma
- (2016) Francesca Murer et al. DIGESTIVE AND LIVER DISEASE
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
- (2015) Irina Kareva et al. CANCER LETTERS
- Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
- (2015) Alessandro Granito et al. DIGESTIVE AND LIVER DISEASE
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Determinants of Survival After Sorafenib Failure in Patients With BCLC-C Hepatocellular Carcinoma in Real-World Practice
- (2015) I-Cheng Lee et al. MEDICINE
- Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
- (2014) Gemma Cramarossa et al. Biomarkers in Medicine
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two Cases
- (2013) Sara Marinelli et al. Hepatitis Monthly
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis
- (2013) R. Lencioni et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
- (2013) Yu-Yun Shao et al. JOURNAL OF HEPATOLOGY
- Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma
- (2013) Omar Abdel-Rahman et al. MEDICAL ONCOLOGY
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments
- (2013) Sheng-Li He WORLD JOURNAL OF GASTROENTEROLOGY
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial
- (2010) Yong Xia et al. ANNALS OF SURGICAL ONCOLOGY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma
- (2009) J. O. Lee et al. ANNALS OF ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started